CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 106 enrolled
Drug / intervention
MK-0873 +1 moredrug
Likely dose
MK-0873 1.25 mg twice daily for 12 weeksAI-extracted
Key inclusion· 2
  • ✓Rheumatoid arthritis diagnosed by American College of Rheumatology criteria
  • ✓Active disease despite current medications
Key exclusion· 3
  • ✕Other major illnesses
  • ✕Past history of certain other disorders
  • ✕Certain prohibited medications

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00132769
NCT00132769Phase 2Completed
CompareCT.gov

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind, 12-Week Study to Assess the Clinical Efficacy, Safety, and Tolerability of MK-0873 in Rheumatoid Arthritis

Merck Sharp & Dohme LLC·interventional·Posted Aug 22, 2005·Updated Jul 30, 2015

In Brief

A Phase 2 clinical trial evaluating MK-0873 and Comparator: Placebo for Rheumatoid Arthritis. Completed, enrolled 106 participants.

Detailed Summary

This study will look at whether this new drug is effective in the treatment of rheumatoid arthritis, and at whether it is safe and well-tolerated by participants with the disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 22, 2005
Enrollment StartJan 1, 2005
Primary CompletionNov 1, 2005
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 20.9 years ago

Interventions

MK-0873drug

MK-0873 1.25 mg twice daily for 12 weeks

Comparator: Placebodrug

Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks